Literature DB >> 21321147

In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?

Giuseppe Togni1, Valeria Battini, Anna Bulgheroni, Federico Mailland, Maurizio Caserini, Werner Mendling.   

Abstract

Bacterial vaginosis is characterized by a shift of the physiological flora to a diverse spectrum of bacteria, where Gardnerella vaginalis and Atopobium vaginae are the most important markers. In this study, the antimicrobial activity of nifuratel against G. vaginalis, A. vaginae, and lactobacilli was compared with that of the two currently used antibiotics metronidazole and clindamycin. Results suggest that nifuratel has a better spectrum of activity, being highly active against G. vaginalis and A. vaginae without affecting lactobacilli.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321147      PMCID： PMC3088278          DOI： 10.1128/AAC.01623-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  What's new in bacterial vaginosis and trichomoniasis?

Authors:  Jack D Sobel
Journal:  Infect Dis Clin North Am       Date:  2005-06       Impact factor: 5.982

2.  High vaginal concentrations of Atopobium vaginae and Gardnerella vaginalis in women undergoing preterm labor.

Authors:  Jean Pierre Menard; Chafika Mazouni; Inesse Salem-Cherif; Florence Fenollar; Didier Raoult; Léon Boubli; Marc Gamerre; Florence Bretelle
Journal:  Obstet Gynecol       Date:  2010-01       Impact factor: 7.661

3.  [Comparative studies on various compounds with trichomonacidal activity].

Authors: 
Journal:  Ginecol Obstet Mex       Date:  1970-11

4.  [Antimicrobial activity of nifuratel].

Authors:  F Dubini; P Furneri
Journal:  G Ital Chemioter       Date:  1985 Sep-Dec

5.  Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections.

Authors:  S E Hawes; S L Hillier; J Benedetti; C E Stevens; L A Koutsky; P Wolner-Hanssen; K K Holmes
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

6.  Antimicrobial susceptibilities of Gardnerella vaginalis.

Authors:  A B Kharsany; A A Hoosen; J Van den Ende
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  Clindamycin versus metronidazole in the treatment of bacterial vaginosis.

Authors:  W L Greaves; J Chungafung; B Morris; A Haile; J L Townsend
Journal:  Obstet Gynecol       Date:  1988-11       Impact factor: 7.661

8.  Adherent biofilms in bacterial vaginosis.

Authors:  Alexander Swidsinski; Werner Mendling; Vera Loening-Baucke; Axel Ladhoff; Sonja Swidsinski; Laura P Hale; Herbert Lochs
Journal:  Obstet Gynecol       Date:  2005-11       Impact factor: 7.661

9.  High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.

Authors:  Catriona S Bradshaw; Anna N Morton; Jane Hocking; Suzanne M Garland; Margaret B Morris; Lorna M Moss; Leonie B Horvath; Irene Kuzevska; Christopher K Fairley
Journal:  J Infect Dis       Date:  2006-04-26       Impact factor: 5.226

10.  Throwing the dice for the diagnosis of vaginal complaints?

Authors:  Andreas Schwiertz; David Taras; Kerstin Rusch; Volker Rusch
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-02-17       Impact factor: 3.944
View more
  7 in total

1.  Antibacterial treatment of bacterial vaginosis: current and emerging therapies.

Authors:  Jean-Pierre Menard
Journal:  Int J Womens Health       Date:  2011-08-23

Review 2.  Bacterial vaginosis, Atopobium vaginae and nifuratel.

Authors:  Franco Polatti
Journal:  Curr Clin Pharmacol       Date:  2012-02-01

3.  Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women.

Authors:  Inês Bártolo; Ana Rita Diniz; Pedro Borrego; João Pedro Ferreira; Maria Rosário Bronze; Helena Barroso; Rui Pinto; Carlos Cardoso; João F Pinto; Rafael Ceña Diaz; Pilar Garcia Broncano; Maria Angel Muñoz-Fernández; Nuno Taveira
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

4.  Efficacy of vitamin C vaginal tablets as prophylaxis for recurrent bacterial vaginosis: a randomised, double-blind, placebo-controlled clinical trial.

Authors:  Vladislav N Krasnopolsky; Vera N Prilepskaya; Franco Polatti; Nina V Zarochentseva; Guldana R Bayramova; Maurizio Caserini; Renata Palmieri
Journal:  J Clin Med Res       Date:  2013-06-21

Review 5.  Anaerobes and bacterial vaginosis in pregnancy: virulence factors contributing to vaginal colonisation.

Authors:  Charlene W J Africa; Janske Nel; Megan Stemmet
Journal:  Int J Environ Res Public Health       Date:  2014-07-10       Impact factor: 3.390

6.  Silver sucrose octasulfate (IASOS™) as a valid active ingredient into a novel vaginal gel against human vaginal pathogens: in vitro antimicrobial activity assessment.

Authors:  Cinzia Marianelli; Paola Petrucci; Maria Cristina Comelli; Gabriella Calderini
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

Review 7.  Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions.

Authors:  Daniela Machado; Joana Castro; Ana Palmeira-de-Oliveira; José Martinez-de-Oliveira; Nuno Cerca
Journal:  Front Microbiol       Date:  2016-01-20       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.